GH
Guardant Health, Inc.
Set alert
- YTD
- +75.05%
- 1 year
- +93.49%
- Open
- 182.48
- Prev close
- 185.31
- Mkt cap
- 23.99B
- Vol
- 1.50M
- Avg vol
- 1.94M
- EPS
- -3.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 175.44
- High
- 185.65
- Forward P/E
- -471.56
- Beta
- 1.58
- Short ratio
- 6.12
- Inst. own
- 100.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 169.49
- 200-d avg
- 130.15
- 1y target
- 202.24
Discussion (4)
Sign in to join the discussion
$GH very interesting ! Did reportedly cross minimum thresholds required by Medicare and Medicaid.
Trading comes with a lot of benefits.I was skeptical and scared of loosing my savings but I'm glad I took the bold step that is now favoring me and my education, visit her Facebook page Magdalena J Gabriel, if you which to take advantage of her work ✅?..
Just got FDA approval.
FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test
Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies — NGS and liquid biopsy — in one diagnostic test in order to guide treatment decisions.
“Approval of a companion diagnostic that uses a liquid biopsy and leverages next-generation sequencing marks a new era for mutation testing,” said Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “In addition to benefitting from less invasive testing, patients are provided with a simultaneous mapping of multiple biomarkers of genomic alterations, rather than one biomarker at a time, which can translate to decreased wait